AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02343484
Drug: Gelified ethanol combined to pulsed radiofrequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
Trial: NCT02343484
Drug: Gelified ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
Trial: NCT00936624
Drug: SOTB07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOTB07 100mg
Trial: NCT00936624
Drug: SOTB07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOTB07 200mg
Trial: NCT00936624
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04480281
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Group Placebo received an equal bolus volume of normal saline solution at induction, and then a continuous infusion started before surgical incision and maintained up until 24h postoperatively
Trial: NCT03436719
Drug: Oral antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole - 500 mg and Erythromycin - 500 mg per os \*3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
Trial: NCT03436719
Drug: Intravenous antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
Trial: NCT00555750
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
Trial: NCT03206723
Drug: Eyedrop
RxNorm normalized name: Autodrop for Eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolone eyedrops 4x/day
Trial: NCT03206723
Drug: Hydrocodone
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocone 1-2 tabs 4x/day if needed
Trial: NCT03752294
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
Trial: NCT02671058
Drug: Hydrocortisone Acetate
RxNorm normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
Trial: NCT01299779
Drug: PEG-ELS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 1L + 500 cc clear liquids at 6 pm night prior~* 1L + 500 cc clear liquids starting 4 hours prior to colonoscopy
Trial: NCT01554111
Drug: phosphosoda rectal enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
Trial: NCT02468323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive regular spinal anesthesia
Trial: NCT01044433
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03893617
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
Trial: NCT01173536
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT00156650
Drug: Testosterone Gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone (T) gel 10 g daily for 6 months
Trial: NCT04397653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Trial: NCT04231292
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03066089
Drug: Fenfuro
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01979016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00266487
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00633022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
Trial: NCT03677401
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Tablets
Trial: NCT01968031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02130973
Drug: Standard Clinical Practice Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Clinical Practice Regimen
Trial: NCT01971411
Drug: Calcium 500mg with 200 IU Vitamin D - 2 tablets daily
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03235141
Drug: azithromycin eye drops by essex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
Trial: NCT00050934
Drug: oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00271583
Drug: CDB-2914
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00366288
Drug: PAZ-417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
Trial: NCT02095574
Drug: [14C]ABT-199 (GDC-0199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]ABT-199 will be administered as a single oral administration
Trial: NCT00480298
Drug: Administration of oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00371137
Drug: Xyrem®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two doses
Trial: NCT00371137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT02013791
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of cyclosporine administered as per protocol
Trial: NCT00927784
Drug: Cryoprotective media alone
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intramyocardial injections of cryoprotective media (placebo).
Trial: NCT01092559
Drug: Nitric Oxide generated by the GeNO nitrosyl delivery system
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
Trial: NCT03580694
Drug: REGN4659
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN4659 will be administered by intravenous (IV) infusion.
Trial: NCT00632242
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
Trial: NCT00632242
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
Trial: NCT00632242
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
Trial: NCT00632242
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment.
Trial: NCT01458977
Drug: Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months
Trial: NCT01458977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
Trial: NCT00632242
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
Trial: NCT04258397
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01932112
Drug: Adenosine arm
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
Trial: NCT02387060
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal administration of fentanyl 25 mcg
Trial: NCT01115725
Drug: Gonal-f® (follitropin alfa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
Trial: NCT02288923
Drug: Pre-medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
Trial: NCT02288923
Drug: Post-operative analgesia - ibuprofen and paracetamol
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
Trial: NCT02288923
Drug: Regular anti emetics
RxNorm normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
Trial: NCT01686217
Drug: ASP015K ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral extended release (ER) at three dosing levels
Trial: NCT01686217
Drug: ASP015K IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral immediate release (IR)
Trial: NCT00095901
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03184649
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is a pre-analgesic will be taken before painful procedures.
Trial: NCT03790488
Drug: JTX-4014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00264004
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg \& 45 mg oral tablet
Trial: NCT01861249
Drug: SAR339658
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous
Trial: NCT01214629
Drug: LY2523355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
Trial: NCT01214629
Drug: LY2523355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
Trial: NCT01710358
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT04385043
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive only standard therapy for Covid-19 infection
Trial: NCT01880385
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
Trial: NCT04391959
Drug: AZR-MD-001 Active
RxNorm normalized name: eptacog alfa activated 0.001 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZR-MD-001 is an active ophthalmic ointment
Trial: NCT02297230
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
Trial: NCT01880385
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
Trial: NCT01712568
Drug: Test Product (Ropinirole)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one Tablet at 0 hour
Trial: NCT04406194
Drug: AVIGAN 200 mg Film Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
Trial: NCT04140591
Drug: Proton-pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI: Pariet EC 20mg/QDAC
Trial: NCT00214864
Drug: docetaxel, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1\&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8
Trial: NCT03649750
Drug: Mucinex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucinex® 600 mg ER bi-layer tablets
Trial: NCT04391959
Drug: AZR-MD-001 Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZR-MD-001 is a vehicle ophthalmic ointment
Trial: NCT00897104
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
Trial: NCT03105193
Drug: IV Saline bolus and infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
Trial: NCT03105193
Drug: IP Saline bolus and infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
Trial: NCT03105193
Drug: IV lignocaine bolus and infusion
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
Trial: NCT03105193
Drug: IP Lignocaine bolus and infusion
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
Trial: NCT03787017
Drug: FDC(MP-513 20mg/Metformin XR 1000mg)
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01097694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00004906
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004906
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00881569
Drug: CS-7017
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-7017 administered orally, twice daily continuously for 6 weeks
Trial: NCT01652638
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
Trial: NCT02966860
Drug: Oral solution OC/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01447095
Drug: Prostacyclin 1 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
Trial: NCT01447095
Drug: Prostacyclin 2 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
Trial: NCT01447095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion with placebo day 5-10 after SAH
Trial: NCT02412423
Drug: post-transplantation cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00269386
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
Trial: NCT00269386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03300687
Drug: FX-322
RxNorm normalized name: Prevail-FX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intratympanic injection
Trial: NCT03300687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intratympanic injection
Trial: NCT02979132
Drug: Eisensulfat LOMAPHARM 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
Trial: NCT04672928
Drug: IBI318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg,iv,Q4W
Trial: NCT01075945
Drug: artemether- lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twenty tablet in eight doses
Trial: NCT04432857
Drug: AN0025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02480114
Drug: Hydrocodone/Acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesia
Trial: NCT02480114
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal Analgesia
Trial: NCT02480114
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NSAID Analgesia
Trial: NCT02480114
Drug: Magic Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution to treat mucositis
Trial: NCT01937559
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no